SCHEMBL7669653

SCHEMBL7669653

O=C(Nc1cc(O)ccn1)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.64
NPC1 O15118 5/20 0.64
ATM Q13315 1/20 0.62
JAK2 O60674 1/20 0.58
TYK2 P29597 1/20 0.58
KMT2A Q03164 4/20 0.56
MEN1 O00255 3/20 0.56
ALDH1A1 P00352 1/20 0.55
HCAR3 P49019 1/20 0.53
MAPK8 P45983 1/20 0.52
MAPK10 P53779 1/20 0.52
PKM P14618 1/20 0.51
DEGS1 O15121 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
CCNA2 P20248 1/20 0.50
CDK2 P24941 1/20 0.50
CCNA1 P78396 1/20 0.50
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1767522 0.87 RAB9A (0.61) RAB9ANPC1ATMJAK2TYK2
SCHEMBL29409167 0.85 RAB9A (0.62) RAB9ANPC1ATMJAK2TYK2
SCHEMBL1569099 0.85 RAB9A (0.62) RAB9ANPC1ATMJAK2TYK2
SCHEMBL24349065 0.83 RAB9A (0.61) RAB9ANPC1ATMJAK2TYK2
SCHEMBL28650577 0.83 JAK2 (0.63) RAB9ANPC1ATMJAK2TYK2
SCHEMBL29899082 0.83 NPC1 (0.61) RAB9ANPC1ATMJAK2TYK2
SCHEMBL28655226 0.83 NPC1 (0.65) RAB9ANPC1ATMJAK2TYK2
SCHEMBL17065565 0.83 NPC1 (0.89) RAB9ANPC1ATMKMT2AMEN1
SCHEMBL30362420 0.83 NPC1 (0.61) RAB9ANPC1ATMJAK2TYK2
SCHEMBL16620629 0.83 NPC1 (0.61) RAB9ANPC1ATMJAK2TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020035092-A1 Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid CELLTECH THERAPEUTICS LIMITED 2002-03-21 US disclosed
US-6319922-B1 ALPHA-PYRIMIDYL-SUBSTITUTED; USEFUL FOR TREATING DISEASES INCLUDING INFLAMMATORY DISEASES, AND DISEASES INVOLVING ANGIOGENESIS, BONE RESORPTION OR CELLULAR OR MATRIX OVER-EXPANSION. CELLTECH THERAPEUTICS LIMITED (GB) 2001-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035092-A1 Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid ITGA1, ITGB1, VCAM1 RAB9A 1743/4885NPC1 2926/4885ATM 4366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.